Antitumor activity of a novel small molecule TLR7 agonist via immune response induction and tumor microenvironment modulation

作者：Diao, Yuwen; Wang, Xiaodong; Wan, Yanyan; Zhong, Jingjing; Gao, Dong; Liu, Yu; Gao, Ningning; Li, Wang; Liu, Bing; Huang, Xinping; Jin, Zhenchao; Peng, Boya; Wang, Zhulin; Fu, Li; Chen, Siping; Jin, Guangyi^*

来源：Oncology Reports, 2016, 35(2): 793-800.

DOI：10.3892/or.2015.4436

• adenine derivatives
• immunotherapy
• toll-like receptor 7 agonist
• solid tumor
• tumor microenvironment

Immunotherapy is emerging as a powerful and active tumor-specific approach against cancer via triggering the immune system. Toll-like receptors (TLRs) are fundamental elements of the immune system, which facilitate our: understanding of the innate and adaptive immune pathways.. TLR agonists used as single agents can effectively eradicate tumors due to their potent stimulation of innate and adaptive immunity. We examined the effects of a novel adenine type of TLR7 agonists on both innate and adaptive immune activation in vitro and in vivo. We established the local and distant tumor-bearing mice derived from murine mammary carcinoma cell line (4T1) to model metastatic disease. Our data demonstrated that SZU101 was able to stimulate innate immune cells to release cytokines at the very high level compared with LPS at the same or lower concentration. Locally intratumoral SZU101 injection can elicit a systemic antitumor effect on murine breast tumor model. SZU101 affected the frequency of intratumoral immune cell infiltration, including the percentage of CD4(+) and CD8(+) increase, and the ratio of Tregs decrease. Our data reveal that the antitumor effect of SZU101 is associated with multiple mechanisms, inducing tumor-specific immune response, activation of innate immune cells and modulation of the tumor microenvironment.

• 出版日期2016-2
• 单位深圳大学; 河北医科大学; 大连医科大学